KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EBITDA: 2011-2024

Historic EBITDA for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to -$320.2 million.

  • Travere Therapeutics' EBITDA rose 146.99% to $25.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$88.6 million, marking a year-over-year increase of 74.61%. This contributed to the annual value of -$320.2 million for FY2024, which is 191.20% down from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' EBITDA is -$320.2 million, which was down 191.20% from -$109.9 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' EBITDA registered a high of -$109.9 million during FY2023, and its lowest value of -$320.2 million during FY2024.
  • In the last 3 years, Travere Therapeutics' EBITDA had a median value of -$280.8 million in 2022 and averaged -$237.0 million.
  • Per our database at Business Quant, Travere Therapeutics' EBITDA surged by 60.85% in 2023 and then slumped by 191.20% in 2024.
  • Over the past 5 years, Travere Therapeutics' EBITDA (Yearly) stood at -$171.1 million in 2020, then dropped by 5.08% to -$179.8 million in 2021, then crashed by 56.23% to -$280.8 million in 2022, then skyrocketed by 60.85% to -$109.9 million in 2023, then tumbled by 191.20% to -$320.2 million in 2024.